Ahead of earnings tomorrow AM. For the most part what the report holds is already known among those who have been following the stock however. It should reveal about 30 percent quarter to quarter gains in Erivedge sales, and probably a better corresponding EPS than the -8 cent estimate. So now the question is will it hold its gains from today, sell the news tomorrow or continue to rise off of the official report of improved sales. The other elephant in the room of course is CHMP this week, and the possible announcement of erivedge approval in Europe early Friday morning.